Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3688 | Sputum analysis Wiki | 1.00 |
| drug1013 | Computed Tomography (CT) Wiki | 1.00 |
| drug593 | Blood analysis Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a longitudinal study of the long-term impact of COVID-19 on the lungs. Participants will be followed over a period of up to 4 years and impacts of COVID-19 on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129, pulmonary function tests, exercise capacity, computed tomography imaging and questionnaires.
Description: Measured using 129-Xenon MRI ventilation defect percent
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by VDP. Time: 1 yearDescription: Measured using forced expiratory volume in one second (FEV1)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FEV1. Time: 1 yearDescription: Measured using forced vital capacity (FVC)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FVC. Time: 1 yearDescription: Measured using total lung capacity (TLC)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by TLC. Time: 1 yearDescription: Functional residual capacity (FRC)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FRC. Time: 1 yearDescription: Measured using residual volume (RV)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by RV. Time: 1 yearDescription: Measured using forced oscillation technique (FOT)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FOT. Time: 1 yearDescription: Measured using lung clearance index (LCI)
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by LCI. Time: 1 yearDescription: Measured using Fractional Exhaled Nitric Oxide (FeNO).
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by FeNO. Time: 1 yearDescription: Exercise capacity measured by six-minute walk test
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by exercise capacity. Time: 1 yearDescription: Measured using the baseline dyspnea index questionnaire.
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by baseline dyspnea index questionnaire Time: 1 yearDescription: Measured using the modified medical research council (mMRC) dyspnea scale questionnaire.
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by (mMRC) dyspnea scale questionnaire. Time: 1 yearDescription: Measured using the COPD assessment test (CAT).
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by CAT. Time: 1 yearDescription: Measured using the St. George's respiratory questionnaire (SGRQ).
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by SGRQ. Time: 1 yearDescription: Measured using the International Physical Activity Questionnaire (IPAQ).
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by IPAQ. Time: 1 yearDescription: Measured using blood and sputum eosinophil count.
Measure: Determine long-term respiratory impairment in COVID-19 survivors who did and did not require hospitalization at one year as measured by eosinophil count. Time: 1 yearDescription: Measured using 129-Xenon MRI ventilation defect percent
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by VDP. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using forced expiratory volume in one second (FEV1).
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FEV1. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using forced vital capacity (FVC)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FVC. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using total lung capacity (TLC)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by TLC. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using functional residual capacity (FRC)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FRC. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using residual volume (RV)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by RV. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using forced oscillation technique (FOT).
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FOT. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using lung clearance index (LCI)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by LCI. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using Fractional Exhaled Nitric Oxide (FeNO)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by FeNO. Time: within 3 months post COVID-19 infection recoveryDescription: Exercise capacity measured by six-minute walk test
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by exercise capacity. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the baseline dyspnea index questionnaire.
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by the baseline dyspnea index questionnaire. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the modified medical research council (mMRC) dyspnea scale questionnaire
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by the mMRC dyspnea scale questionnaire. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the COPD assessment test (CAT)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by CAT. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the St. George's respiratory questionnaire (SGRQ)
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by SGRQ. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using the International Physical Activity Questionnaire (IPAQ).
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by IPAQ. Time: within 3 months post COVID-19 infection recoveryDescription: Measured using blood and sputum eosinophil count.
Measure: Determine the clinical, structural, physiologic, and imaging biomarkers within 3 months post COVID-19 infection recovery as measured by eosinophil count.. Time: within 3 months post COVID-19 infection recoveryDescription: Evaluated by assessing different genders.
Measure: Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by sex. Time: up to 4 yearsDescription: Evaluated by assessing different age groups.
Measure: Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by age. Time: up to 4 yearsDescription: Evaluated by assessing smoking history measured in pack-years.
Measure: Determine if COVID-19-induced respiratory impairment and predictors of respiratory impairment differ by smoking history measured in pack-years. Time: up to 4 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports